After development of specific inhibitors targeting BET BDs, BET factors, especially Brd4, emerged as key regulators of transcription and as promising targets in the therapy of cancer and immunoinflammatory diseases (Fujisawa and Filippakopoulos, 2017; Wang et al., 2021). Here, BRD4 is linked to cancer.